Work

mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2

Year: 2022

Type: article

Source: Med

DOI: 10.1016/j.medj.2022.03.009

Authors: Tamarand L. Darling, Baoling Ying, Bradley Whitener, Laura A. VanBlargan, Traci L. Bricker, Chieh-Yu Liang, Astha Joshi, Gayan Bamunuarachchi, Kuljeet Seehra, Aaron J. Schmitz, Peter J. Halfmann, Yoshihiro Kawaoka, Sayda M. Elbashir, Darin K. Edwards, Larissa B. Thackray, Michael S. Diamond, Adrianus C.M. Boon

Institutions: Washington University in St. Louis, University of Wisconsin–Madison, National Center for Global Health and Medicine, Institute of Medical Science, The University of Tokyo, The University of Tokyo, Moderna Therapeutics (United States)

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Japan Agency for Medical Research and Development, National Institutes of Health, National Institute of Allergy and Infectious Diseases

Awards: G103575219, Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2, G1277313600, Emerging infections: surveillance, epidemiology and pathogenesis, G3989356997, G4102728913, G5204974984, G535802159, G5982071039, G7059131728, G719751075, G7314510119, G7790317656, G8737024107, G8852738732, G951058115

OpenAlex ID: W4225791191

FWCI: 1.833

Cites: 51

Cited by: 16

Related to: 10